Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs

New offering helps health systems strengthen financial confidence, operational readiness and program scalability to support broader patient access to cell and gene therapies

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.

“Cell and gene therapies have the potential to transform care for patients with serious and complex diseases, but delivering them requires coordinated execution across strategy, finance, clinical operations, pharmacy and patient access,” said Ryan Telford, Vice President, Health System Pharmacy Portfolio Strategy at Accelerate Pharmacy Solutions, Cencora. “We’re building on our existing capabilities to provide health systems with tailored support – from market landscape and readiness assessments to governance design, implementation and optimization – to help them launch or expand their CGT programs.”

More than 35 CGTs have been approved by the U.S. Food and Drug Administration (FDA), and more than 1,700 clinical trials are underway globally, including products targeting indications with larger patient populations. Yet only 4% of health system pharmacy leaders surveyed in a recent report said their organizations were fully prepared to integrate these therapies, underscoring the need for stronger infrastructure, resource allocation and operational alignment to alleviate barriers to care.

Accelerate Pharmacy Solutions’ CGT Enablement team will provide health systems with tailored support across three key areas:

• Financial confidence: CGT market assessment, including therapy-specific financial considerations, reimbursement dynamics and site-of-care considerations.
• Operational readiness: Support for program launch or expansion through readiness assessments, gap analysis, strategic roadmap development, governance design and workflow planning.
• Scalable growth: Helping establish repeatable operating models to drive coordinated execution across strategy, finance, clinical operations, pharmacy and patient access teams and support expansion across therapies, sites and indications.

A leader in specialty pharmaceutical services, Cencora provides integrated CGT solutions across the product lifecycle, including commercialization support to help developers bring products to market, as well as specialty distribution and provider solutions to support reliable, efficient access across sites of care. Combined with Accelerate Pharmacy Solutions’ patient delivery expertise, this offering expands Cencora’s CGT capabilities and strengthens the support the company provides to healthcare providers to reduce barriers and improve access.

"Fulfilling the clinical promise of these therapies is heavily dependent on health systems strategically expanding their capabilities," said Louis Cicchini, Senior Director, Scientific Affairs and Strategic Partnerships, CGT Service Line at Cencora. "As an industry, we have to collaborate across silos to sustainably deliver advanced therapies and make accessing that care easier for patients. Investing in solutions to support and elevate the care model is a win for patients, providers and developers."

An integrated portfolio of pharmacy and supply chain solutions, Accelerate Pharmacy Solutions pairs industry-leading technology with deep pharmacy and supply chain expertise to help health systems build, grow and optimize their pharmacy programs.

For more information about Accelerate Pharmacy Solutions and CGT Enablement, visit: www.cencora.com/solutions/cell-and-gene-therapy-enablement

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products and solutions. Our worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #16 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at www.cencora.com.